FDA Links Liver Damage with Mavyret, Zepatier, and Vosevi
The FDA Issues a Drug Safety Communication Warning of Liver Failure, Damage, and Injury Caused by Hepatitis C Medicines - Mavyret, Zepatier, and Vosevi. (08/28/2019) WASHINGTON, D.C. — On August 28, 2019, the FDA released a “Drug Safety Communication” stating that prescription medications containing a hepatitis C virus (“HCV”) … [Read more...] about FDA Links Liver Damage with Mavyret, Zepatier, and Vosevi
FDA Hepatitis Medication Announcement Clarifies Liver Risks
On Aug. 28, 2019, the United States Food and Drug Administration issued a statement regarding medicine used to treat hepatitis C. The FDA hepatitis medication announcement described the rare potential of certain drugs being poorly prescribed, resulting in liver damage and failures. Interpreting The FDA Hepatitis Medication … [Read more...] about FDA Hepatitis Medication Announcement Clarifies Liver Risks
